Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. — VialBase Research

Summary

This study examined how Thymalin — described by the authors as a polypeptide complex isolated from the thymus that regulates immune system function, with reported efficacy in acute respiratory syndrome, chronic obstructive bronchitis, and other immunopathology — influences the differentiation of human hematopoietic stem cells (HSC) and the expression of the CD28 molecule implicated in antiviral immunity. The authors report that Thymalin reduced expression of CD44 (a stem cell marker) and CD117 (a marker of the intermediate stage of HSC differentiation) by 2-3 times, while increasing expression of CD28, a marker of mature T lymphocytes, by 6.8 times. They read this marker shift as indirect evidence that Thymalin pushes CD117+ cells toward differentiation into mature CD28+ T lymphocytes. From there the paper builds a COVID-19 hypothesis: because patients with severe COVID-19 show decreased blood counts of CD28+, CD4+, and CD8+ T lymphocytes — a sign of pronounced immune suppression — the authors propose that Thymalin’s antiviral effect may consist of compensatory stimulation of HSC differentiation into CD28+ T lymphocytes during that suppression, and suggest Thymalin be considered an immunoprotective peptide drug for COVID-19 prevention. That final step is explicitly a proposal built on marker data, not a clinical finding; the study presents no patient outcomes. The authors themselves note that the targeted molecular mechanism of Thymalin’s biological activity requires further study.

Key Findings

• Thymalin reduced expression of the stem cell marker CD44 and the intermediate-differentiation marker CD117 by 2-3 times in human hematopoietic stem cells
• Thymalin increased expression of CD28, the mature T lymphocyte marker, by 6.8 times
• The authors interpret the combined marker shift as indirect evidence of stimulated differentiation from CD117+ cells into mature CD28+ T lymphocytes
• The paper states that severe COVID-19 is accompanied by decreased CD28+, CD4+, and CD8+ T lymphocytes, indicating pronounced immune suppression, and proposes Thymalin as a compensatory stimulus — a hypothesis, not a demonstrated clinical effect
• The authors state directly that the targeted molecular mechanism of Thymalin’s biological activity requires further study

Relevance to Thymalin

This is the mechanistic backbone most often cited when Thymalin is sold as an immune-support or “thymus-restoration” peptide, and on its own terms it is a reasonable piece of work: a 6.8-fold increase in CD28 expression alongside a 2-3-fold drop in progenitor markers is a coherent differentiation signal. What it is not is evidence of clinical immune benefit in a human being. Surface-marker expression in the laboratory is several inferential steps removed from infection resistance, immune reconstitution, or any COVID-19 endpoint, and the paper’s COVID-19 conclusion is framed by its own authors as a possibility (“it is possible that…”), not a result. The work also comes from the Khavinson group, the originators and promoters of the compound, so it inherits the same single-source provenance limitation as the rest of the Thymalin literature. Treat this note as a plausible mechanism worth describing honestly, and pair it with the explicit statement that no independent clinical trial has confirmed the downstream benefit.

Citation

Khavinson VK, Linkova NS, Kvetnoy IM, et al. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bulletin of experimental biology and medicine. 2020;170(1):118-122. doi:10.1007/s10517-020-05016-z.

See Also

• Parent compound: Thymalin